Tech scans begin to form the basis of an engineered cell therapy translational ecosystem

CAR-T molecule

In this post, Maik Luu highlights the value of the ‘tech scan’ approach that the IMI funded T2EVOLVE project has implemented to build awareness and foster collaboration. T2EVOLVE aims to resolve bottlenecks in the development of engineered cell therapies. It is a large scale public/private partnership. In comparison with other consortium projects, we have supported the members of T2EVOLVE have rapidly adopted a consortium science mindset.

The tech scans and the stakeholder community are the first steps towards building a wider ecosystem around engineered cell therapy. Science translational medicine has said that cell therapy will be the third pillar of medicine after small molecules and biological therapies.

How fast that is achieved will be directly proportional to the degree that which the wider community is willing to work together to solve innovation bottlenecks and exploit synergies.

Our main role in T2EVOLVE is to build a community that evolves into an ecosystem that carries the vision of T2EVOLVE forward. If you have an interest in cellular therapeutics or another topic that you think would benefit from the development of a translational ecosystem get in touch.